LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study

Masakazu Ichinose (Sendai, Japan), Masakazu Ichinose, Yoshinosuke Fukuchi, Koichiro Tatsumi, Hiromasa Inoue, Toshihisa Arai, Kai Shibata, Hideaki Miyagishi, Yukinori Sakata

Source: International Congress 2015 – Emerging strategies for airway disease treatments
Session: Emerging strategies for airway disease treatments
Session type: Thematic Poster Session
Number: 4359
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Masakazu Ichinose (Sendai, Japan), Masakazu Ichinose, Yoshinosuke Fukuchi, Koichiro Tatsumi, Hiromasa Inoue, Toshihisa Arai, Kai Shibata, Hideaki Miyagishi, Yukinori Sakata. LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study. Eur Respir J 2015; 46: Suppl. 59, 4359

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016


Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007



A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013

Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study.
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013



Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015


Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial
Source: Annual Congress 2010 - COPD exacerbation
Year: 2010

RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021



LATE-BREAKING ABSTRACT: Oxygen titration and weaning with FreeO2 in COPD patients hospitalized for exacerbation. A randomized controlled pilot study
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015


Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial
Source: International Congress 2019 – Airway infection in COPD
Year: 2019

Roflumilast for stable COPD: Meta-analysis of randomized controlled trials
Source: International Congress 2014 – Clinical presentations
Year: 2014


Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study
Source: Eur Respir J, 58 (1) 2001798; 10.1183/13993003.01798-2020
Year: 2021



RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
Source: Eur Respir J 2002; 20: 245
Year: 2002


A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

LATE-BREAKING ABSTRACT: Treating the most diseased segments in patients with severe emphysema: 6 month results from the STEP-UP randomized controlled trial (RCT)
Source: International Congress 2015 – Advances in therapeutic bronchoscopy
Year: 2015


A double-blind, randomized, sham-controlled study of Targeted Lung Denervation in patients with moderate to severe COPD : AIRFLOW-2 One Year Outcomes
Source: International Congress 2019 – Interventional pulmonology: a mixture of spices
Year: 2019



Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial
Source: International Congress 2016 – Asthma management
Year: 2016


Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014